Last updated: June 16, 2026
Litigation summary and analysis: Eagle Pharmaceuticals, Inc. v. Hospira, Inc., 1:18-cv-01074-CFC
Eagle Pharmaceuticals, Inc. v. Hospira, Inc. (D. Del., CFC, 1:18-cv-01074-CFC) is a Hatch-Waxman patent infringement case tied to Hospira’s generic or authorized-generic entry efforts against an Eagle product. The docket outcome, asserted patents, claim construction, and whether any settlement or consent judgment occurred are not provided in the input. Without those core record facts (asserted Orange Book patents, specific patent numbers and expiration dates, infringement theories, and final judgment/settlement terms), a complete, accurate litigation summary and enforceable legal analysis cannot be produced.
What is the case posture in Eagle Pharmaceuticals v. Hospira (1:18-cv-01074-CFC)?
Case posture summary requires docket-level facts: complaint date, amended complaints, asserted patents and counts, motions to dismiss or transfer, preliminary injunction practice, Markman schedule, summary judgment decisions, and final disposition (jury verdict, bench judgment, dismissal with prejudice, or consent judgment). None of those items are contained in the provided information.
What parties and filings define the posture?
The minimum dataset for a litigation posture analysis includes:
- Complaint and amended complaint dates
- Asserted patents (numbers)
- Paragraph IV status tied to specific FDA applications (ANDA/505(b)(2) or supplements)
- Claims asserted (independent method vs. composition vs. formulation)
- Procedural rulings (motions to dismiss, transfer, stay, claim construction)
- Trial schedule outcomes
- Final judgment or settlement record
What court rulings typically drive value here?
In Hatch-Waxman litigation, value turns on:
- Claim construction outcomes (scope of claims impacting “at least one” limitation and component ranges)
- Validity rulings (anticipation, obviousness, indefiniteness, written description/enablement)
- Infringement rulings tied to generic composition or labeling
- Stay status under 21 U.S.C. § 355(j)(5)(B) (or earlier FDA-driven timeline effects)
No rulings are included in the supplied prompt.
Which patents did Eagle assert against Hospira in 1:18-cv-01074-CFC?
A patent-by-patent analysis requires:
- Patent numbers
- Publication/application details (if relevant to construction)
- Expiration and pediatric exclusivity links
- Orange Book listing for the Eagle NDA/Orange Book reference listed drug (RLD)
- Asserted claims per patent (claim numbers)
The prompt does not include asserted patent identities.
How many patents were in the asserted set?
Litigation strategy and risk depends on the count and type:
- Method-of-use vs. formulation/composition vs. manufacturing method
- Number of asserted claims per patent
- Whether “platform” patents are asserted alongside product-specific patents
No asserted set information is provided.
What were the expiration and exclusivity windows?
Patent expiration and any regulatory exclusivities (NCE, pediatric exclusivity) are essential for:
- The “when can a generic launch” timeline
- The materiality of any invalidity or non-infringement ruling
- Settlement incentives (typical reverse payment or licensing patterns)
No expiration/exclusivity data is included.
What happened procedurally: motions, claim construction, and summary judgment?
A reliable litigation summary must track:
- Motions to dismiss (35 U.S.C. § 101/102/103/112 or jurisdictional issues)
- Discovery disputes and protective orders
- Claim construction (Markman) outcomes
- Expert testimony rulings
- Summary judgment disposition (in whole or in part)
- Trial and post-trial rulings if the case proceeded past dispositive motion stages
None of these procedural events are present in the prompt.
What did the final judgment or settlement terms require?
For business impact, the record needs:
- Whether Hospira was enjoined (partial or full)
- Whether Eagle obtained a finding of infringement and/or injunction
- Whether the case ended via settlement and the effective trigger dates
- Any license scope, royalty obligations, or stipulations
- Whether the court entered a consent judgment or dismissal with prejudice
No final outcome terms are provided.
How strong was the asserted patent estate, based on litigation conduct and rulings?
Strength analysis in a Hatch-Waxman case depends on:
- Claim construction direction (narrow vs. broad)
- Invalidity results (prior art mapping quality; anticipation vs. obviousness)
- Written description/enablement outcomes that indicate claim vulnerability
- Whether infringement survived claim narrowing
No rulings or outcomes are provided.
How does this litigation map to Orange Book patents and FDA entry risk?
An Orange Book mapping requires:
- The RLD name
- The ANDA/supplement/application identifier tied to Hospira’s entry attempt
- Each listed patent and its “delisting” status, if any
- The “fuse” of exclusivities and patent expiry dates impacting generic design-around
None of the Orange Book listing and FDA linkage facts are included.
What is the Orange Book status of the patents at issue?
A complete answer requires at minimum:
- Patent list, expiration dates, and active/inactive status
- Whether Hospira filed a Paragraph IV certification to specific patents
- Whether any patents were withdrawn or amended post-filing
No Orange Book details are supplied.
What generic entry risks did Hospira face from Eagle’s claims?
Risk analysis ties to:
- Non-infringement design-around feasibility
- Likelihood of injunction
- Time-to-launch blocked by court rulings or FDA exclusivity
- Settlement leverage based on remaining patent life
No infringement conclusions, remaining term, or injunction posture is provided.
What licensing or settlement patterns typically follow this case category?
Because no settlement terms are given, the analysis cannot identify:
- Whether there was an authorized generic license
- Whether there was a “carve-out” for certain dosages or strengths
- Whether a covenant not to sue applied, and for which products or form factors
No settlement record is included.
How does Eagle’s estate compare with other challengers in the same portfolio?
A comparative assessment requires:
- Other litigations involving Eagle’s product(s)
- Shared patents asserted across cases
- Consistent claim constructions that affect all challengers
No related cases, portfolios, or asserted patents are included.
Timeline of key litigation events in 1:18-cv-01074-CFC
A litigation timeline requires actual dated events from the docket:
- Filing date of complaint
- Amended complaint filings
- Markman hearing date and ruling date
- Summary judgment deadlines and decisions
- Trial dates or dispositive resolution dates
- Settlement/consent judgment/dismissal date
No dated docket events are provided in the prompt.
Key Takeaways
- A complete litigation summary and analysis for Eagle Pharmaceuticals, Inc. v. Hospira, Inc., 1:18-cv-01074-CFC requires asserted-patent identities, procedural rulings, and the final disposition.
- The provided input contains only the case caption and docket number, which is insufficient to produce a fact-accurate summary tied to patents, FDA entry, claim construction outcomes, or business impact.
FAQs
-
What patents were asserted in Eagle Pharmaceuticals v. Hospira (1:18-cv-01074-CFC)?
The asserted patents are not included in the provided information.
-
Did the court issue a preliminary injunction in 1:18-cv-01074-CFC?
The injunction posture is not included in the provided information.
-
Was there a Markman (claim construction) ruling, and how did it affect claim scope?
Claim construction outcomes are not included in the provided information.
-
Did the case settle, and what were the settlement triggers for generic entry?
Settlement terms or entry triggers are not included in the provided information.
-
Which FDA application (ANDA) and Paragraph IV certifications were at issue?
The FDA application linkage and certification details are not included in the provided information.
References
(No sources cited because no record details, docket rulings, or patent assertions were provided in the prompt.)
